R10255 |
LY2874455; dovitinib |
LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM
|
R10256 |
Blu9931 |
BLU9931 is a potent, highly selective, and irreversible fibroblast growth factor
|
R10258 |
Sofosbuvir;PSI-7977; GS7977 |
Sofosbuvir (PSI-7977, GS-7977) is a HCV NS5B polymerase inhibitor for the treatm
|
R10259 |
AG490 |
AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free
|
R10260 |
Sotagliflozin; LP802034; LX4211 |
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
|
R10261 |
CDC0032 Intermediate |
CAS NO.:1282514-63-9Product Name:Synonyms:EINEC:Molecular Formula:Molecular Weig
|
R10262 |
LY294002 |
LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of
|
R10264 |
RO3280 |
RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with
|
R10266 |
GlyH101;GlyH-101 |
GlyH-101 is a cell-permeable glycinyl hydrazone compound that blocks CFTR with K
|
R10268 |
KN-93;KN93 |
KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent kinase II (CaMKII),
|
R10269 |
FG-2216 (Synonyms: IOX3; YM311) |
FG-2216 is a potent HIF-prolyl hydroxylase inhibitor with IC50 of 3.9 uM for PDH
|
R10270 |
GSK2801 |
GSK2801 is a selective bromodomains BAZ2A/B inhibitor with KD of 257 nM and 136
|
R10271 |
BI 2536;BI2536 |
BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respecti
|
R10272 |
Lersivirine(UK-453061) |
Lersivirine(UK-453061) is a next-generation non-nucleoside reverse transcriptase
|
R10273 |
G007-LK |
G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46
|
R10274 |
Piperlongumine |
Piperlongumine, a natural alkaloid from Piper longum L., increases the level of
|
R10275 |
Omarigliptin; MK3102 Intermediate1 |
Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor wit
|
R10276 |
Omarigliptin; MK3102 Intermediate2 |
Omarigliptin(MK-3102) is a potent, selective and long-acting DPP-4 inhibitor wit
|
R10277 |
AZD9291Intermediate3 |
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
|
R10278 |
AZD9291Intermediate4 |
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
|
R10279 |
AZD9291Intermediate5 |
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibi
|
R10280 |
CAL101 Intermediate1 |
CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
|
R10281 |
CAL101 Intermediate2 |
CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
|
R10282 |
CAL101 Intermediate3 |
CAL-101 (Idelalisib, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM
|
R10283 |
Nintedanib esylate; BIBF1120 esylate |
Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3,
|